TuHURA Biosciences Expands Patent Coverage for VISTA Inhibitor TBS-2025
Event summary
- TuHURA Biosciences received U.S. Patent No. 12,760,104 for its VISTA inhibitor TBS-2025, broadening coverage to include bispecific/multispecific antibodies and combinations with other therapies.
- The patent extends protection to treatments beyond cancer, including autoimmune diseases and infections, with a term extending to February 18, 2042.
- TBS-2025 is currently in a Phase 1b clinical trial for mutNPM1 relapsed/refractory AML.
- TuHURA's CEO highlighted the patent's value in expanding therapeutic applications and attracting corporate collaborators.
The big picture
TuHURA's patent expansion for TBS-2025 strengthens its position in the competitive immuno-oncology space, particularly as VISTA emerges as a critical target in blood cancers and beyond. The move aligns with broader industry trends toward combination therapies and the repurposing of cancer drugs for autoimmune and infectious diseases. The patent's long-term coverage could enhance TuHURA's valuation and strategic options.
What we're watching
- Therapeutic Expansion
- Whether TuHURA can successfully transition TBS-2025 into autoimmune and infectious disease markets.
- Clinical Progress
- The pace at which the Phase 1b trial for TBS-2025 in AML advances and yields data.
- Strategic Partnerships
- How the expanded patent protection influences potential collaborations or acquisitions.
Related topics
